TT-00973 / TransThera Biosci - LARVOL DELTA

TransThera Raises HK$190 Million via H-Share Placing to Fund Tinengotinib Trials and Pipeline R&D (TipRanks) - "TransThera Sciences...is advancing a portfolio of innovative drug candidates centered on its core oncology asset Tinengotinib, alongside other molecules including TT-00973 and TT-01488, targeting specialized treatment needs and reinforcing its presence in the innovative drug development space."

Financing • Oncology

Phase 1 study of TT-00973-MS' a highly selective and potent AXL inhibitor' in patients with advanced solid tumors. (ASCO 2025) - P1 | "The preliminary findings from this phase I study demonstrated that the AXL inhibitor TT-00973-MS monotherapy exhibits a well-tolerable safety profile, promising pharmacodynamic activity, with early signs of efficacy in pts with heavily pre-treated advanced solid tumors. Further studies are warranted to comprehensively evaluate the efficacy and safety of TT-00973-MS in large patient populations and specific tumor types. Clinical trial information: NCT05673538"

Clinical • IO biomarker • Metastases • P1 data • Dyslipidemia • Hypertriglyceridemia • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Renal Disease • Solid Tumor • GAS6

TT-00973-MS Tablets in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: TransThera Sciences (Nanjing), Inc.

Metastases • New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor